Drug Profile
Bucillamine - Revive Therapeutics
Alternative Names: REV-002; REV-004; REV-005Latest Information Update: 01 Apr 2024
Price :
$50
*
At a glance
- Originator Revive Therapeutics
- Class Antigouts; Antivirals; Cysteines; Disease-modifying antirheumatics; Nonsteroidal anti-inflammatories; Small molecules; Sulfhydryl compounds; Sulfur amino acids
- Mechanism of Action Antioxidants; Chelating agents; Immunomodulators; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III COVID 2019 infections
- Phase II Cystinuria; Gout
- Research Unspecified
- No development reported Hepatolenticular degeneration
Most Recent Events
- 27 Mar 2024 Revive Therapeutics submits Type C meeting request to the US FDA for Post acute COVID-19 syndrome
- 01 Feb 2024 Revive Therapeutics plans to meet US FDA and international health regulatory bodies for the submission of a phase II/III trial protocol though a type C meeting for Post acute COVID 19 syndrome
- 01 Feb 2024 Revive Therapeutics plans a phase II/III trial for Post acute COVID 19 syndrome in USA (PO)